Abstract
Background: Cancer patients can suffer from psychological and cognitive disorders after chemotherapy, which influence quality of life. Objective: Oxidative stress may contribute to the psychological and cognitive disorders induced in rats by chemotherapy. In the present study, we examined the effects of N-acetylcysteine, an anti-oxidant, on anxiety-like behavior and cognitive impairment in rats treated with a combination of doxorubicin and cyclophosphamide. Methods: Rats were intraperitoneally injected with doxorubicin and cyclophosphamide once a week for 2 weeks. The light-dark test and the novel location recognition test were used to assess anxiety-like behavior and spatial cognition, respectively. The rats’ hippocampal levels of glutathione (GSH) and glutathione disulfide (GSSG) were measured using a GSSG/GSH quantification kit. Results: Combined treatment with doxorubicin and cyclophosphamide produced anxiety-like behavior and cognitive impairment in rats. N-acetylcysteine reversed the anxiety-like behavior and inhibition of novel location recognition induced by the combination treatment. Furthermore, the combination of doxorubicin and cyclophosphamide significantly reduced the rats’ hippocampal GSH/GSSG ratios. N-acetylcysteine reversed the reduction in the GSH/GSSG ratio seen in the doxorubicin and cyclophosphamide-treated rats. Conclusion: These results suggest that N-acetylcysteine inhibits doxorubicin and cyclophosphamide-induced anxiety-like behavior and cognitive impairment by reducing oxidative stress in the hippocampus.
References
1.
Nakamura
Y
, Kitamura
Y
, Sumiyoshi
Y
, Naito
N
, Kan
S
, Ushio
S
, et al. Involvement of 5-HT2A receptor hyperfunction in the anxiety-like behavior induced by doxorubicin and cyclophosphamide combination treatment in rats
. J Pharmacol Sci
. 2018
Nov
;138
(3
):192
–7
.
[PubMed]
1347-86132.
Kitamura
Y
, Hattori
S
, Yoneda
S
, Watanabe
S
, Kanemoto
E
, Sugimoto
M
, et al. Doxorubicin and cyclophosphamide treatment produces anxiety-like behavior and spatial cognition impairment in rats: possible involvement of hippocampal neurogenesis via brain-derived neurotrophic factor and cyclin D1 regulation
. Behav Brain Res
. 2015
Oct
;292
:184
–93
.
[PubMed]
0166-43283.
Kitamura
Y
, Kanemoto
E
, Sugimoto
M
, Machida
A
, Nakamura
Y
, Naito
N
, et al. Influence of nicotine on doxorubicin and cyclophosphamide combination treatment-induced spatial cognitive impairment and anxiety-like behavior in rats
. Naunyn Schmiedebergs Arch Pharmacol
. 2017
Apr
;390
(4
):369
–78
.
[PubMed]
0028-12984.
Stafford
L
, Judd
F
, Gibson
P
, Komiti
A
, Mann
GB
, Quinn
M
. Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome
. Support Care Cancer
. 2015
Aug
;23
(8
):2215
–24
.
[PubMed]
0941-43555.
Wittmann
M
, Vollmer
T
, Schweiger
C
, Hiddemann
W
. The relation between the experience of time and psychological distress in patients with hematological malignancies
. Palliat Support Care
. 2006
Dec
;4
(4
):357
–63
.
[PubMed]
1478-95156.
Ahles
TA
, Saykin
AJ
, Furstenberg
CT
, Cole
B
, Mott
LA
, Skalla
K
, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma
. J Clin Oncol
. 2002
Jan
;20
(2
):485
–93
.
[PubMed]
0732-183X7.
Brezden
CB
, Phillips
KA
, Abdolell
M
, Bunston
T
, Tannock
IF
. Cognitive function in breast cancer patients receiving adjuvant chemotherapy
. J Clin Oncol
. 2000
Jul
;18
(14
):2695
–701
.
[PubMed]
0732-183X8.
Schagen
SB
, van Dam
FS
, Muller
MJ
, Boogerd
W
, Lindeboom
J
, Bruning
PF
. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma
. Cancer
. 1999
Feb
;85
(3
):640
–50
.
[PubMed]
0008-543X9.
Tchen
N
, Juffs
HG
, Downie
FP
, Yi
QL
, Hu
H
, Chemerynsky
I
, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer
. J Clin Oncol
. 2003
Nov
;21
(22
):4175
–83
.
[PubMed]
0732-183X10.
Tannock
IF
, Ahles
TA
, Ganz
PA
, Van Dam
FS
. Cognitive impairment associated with chemotherapy for cancer: report of a workshop
. J Clin Oncol
. 2004
Jun
;22
(11
):2233
–9
.
[PubMed]
0732-183X11.
Merzoug
S
, Toumi
ML
, Boukhris
N
, Baudin
B
, Tahraoui
A
. Adriamycin-related anxiety-like behavior, brain oxidative stress and myelotoxicity in male Wistar rats
. Pharmacol Biochem Behav
. 2011
Oct
;99
(4
):639
–47
.
[PubMed]
0091-305712.
Butterfield
DA
, Lauderback
CM
. Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress
. Free Radic Biol Med
. 2002
Jun
;32
(11
):1050
–60
.
[PubMed]
0891-584913.
Moreira
PI
, Smith
MA
, Zhu
X
, Nunomura
A
, Castellani
RJ
, Perry
G
. Oxidative stress and neurodegeneration
. Ann N Y Acad Sci
. 2005
Jun
;1043
(1
):545
–52
.
[PubMed]
0077-892314.
Tangpong
J
, Cole
MP
, Sultana
R
, Joshi
G
, Estus
S
, Vore
M
, et al. Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity
. Neurobiol Dis
. 2006
Jul
;23
(1
):127
–39
.
[PubMed]
0969-996115.
Cardoso
S
, Santos
RX
, Carvalho
C
, Correia
S
, Pereira
GC
, Pereira
SS
, et al. Doxorubicin increases the susceptibility of brain mitochondria to Ca(2+)-induced permeability transition and oxidative damage
. Free Radic Biol Med
. 2008
Nov
;45
(10
):1395
–402
.
[PubMed]
0891-584916.
Singh
S
, Kumar
A
. Protective effect of edaravone on cyclophoshamide induced oxidative stress and neurotoxicity in rats
. Curr Drug Saf
. 2019
;14
(3
):209
–16
. 1574-886317.
Bouayed
J
, Rammal
H
, Younos
C
, Soulimani
R
. Positive correlation between peripheral blood granulocyte oxidative status and level of anxiety in mice
. Eur J Pharmacol
. 2007
Jun
;564
(1-3
):146
–9
.
[PubMed]
0014-299918.
Santos
P
, Herrmann
AP
, Benvenutti
R
, Noetzold
G
, Giongo
F
, Gama
CS
, et al. Anxiolytic properties of N-acetylcysteine in mice
. Behav Brain Res
. 2017
Jan
;317
:461
–9
.
[PubMed]
0166-432819.
Lomeli
N
, Di
K
, Czerniawski
J
, Guzowski
JF
, Bota
DA
. Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats
. Free Radic Biol Med
. 2017
Jan
;102
:274
–86
.
[PubMed]
0891-584920.
Dean
O
, Giorlando
F
, Berk
M
. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
. J Psychiatry Neurosci
. 2011
Mar
;36
(2
):78
–86
.
[PubMed]
1180-488221.
Joshi
G
, Hardas
S
, Sultana
R
, St Clair
DK
, Vore
M
, Butterfield
DA
. Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: implication for chemobrain
. J Neurosci Res
. 2007
Feb
;85
(3
):497
–503
.
[PubMed]
0360-401222.
Berk
M
, Malhi
GS
, Gray
LJ
, Dean
OM
. The promise of N-acetylcysteine in neuropsychiatry
. Trends Pharmacol Sci
. 2013
Mar
;34
(3
):167
–77
.
[PubMed]
0165-614723.
Egashira
N
, Shirakawa
A
, Abe
M
, Niki
T
, Mishima
K
, Iwasaki
K
, et al. N-acetyl-L-cysteine inhibits marble-burying behavior in mice
. J Pharmacol Sci
. 2012
;119
(1
):97
–101
.
[PubMed]
1347-861324.
Vukovic
R
, Kumburovic
I
, Joksimovic Jovic
J
, Jovicic
N
, Katanic Stankovic
JS
, Mihailovic
V
, et al. N-Acetylcysteine Protects against the Anxiogenic Response to Cisplatin in Rats
. Biomolecules
. 2019
Dec
;9
(12
):9
.
[PubMed]
2218-273X25.
Hotopf
M
, Chidgey
J
, Addington-Hall
J
, Ly
KL
. Depression in advanced disease: a systematic review Part 1. Prevalence and case finding
. Palliat Med
. 2002
Mar
;16
(2
):81
–97
.
[PubMed]
0269-216326.
Somers
JM
, Goldner
EM
, Waraich
P
, Hsu
L
. Prevalence studies of substance-related disorders: a systematic review of the literature
. Can J Psychiatry
. 2004
Jun
;49
(6
):373
–84
.
[PubMed]
0706-743727.
Falleti
MG
, Sanfilippo
A
, Maruff
P
, Weih
L
, Phillips
KA
. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature
. Brain Cogn
. 2005
Oct
;59
(1
):60
–70
.
[PubMed]
0278-262628.
Dix
SL
, Aggleton
JP
. Extending the spontaneous preference test of recognition: evidence of object-location and object-context recognition
. Behav Brain Res
. 1999
Mar
;99
(2
):191
–200
.
[PubMed]
0166-432829.
Pfaffl
MW
. A new mathematical model for relative quantification in real-time RT-PCR
. Nucleic Acids Res
. 2001
May
;29
(9
):e45
.
[PubMed]
0305-104830.
Uttara
B
, Singh
AV
, Zamboni
P
, Mahajan
RT
. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options
. Curr Neuropharmacol
. 2009
Mar
;7
(1
):65
–74
.
[PubMed]
1570-159X31.
Smith
CV
, Jones
DP
, Guenthner
TM
, Lash
LH
, Lauterburg
BH
. Compartmentation of glutathione: implications for the study of toxicity and disease
. Toxicol Appl Pharmacol
. 1996
Sep
;140
(1
):1
–12
.
[PubMed]
0041-008X32.
Pompella
A
, Visvikis
A
, Paolicchi
A
, De Tata
V
, Casini
AF
. The changing faces of glutathione, a cellular protagonist
. Biochem Pharmacol
. 2003
Oct
;66
(8
):1499
–503
.
[PubMed]
0006-295233.
Gaman
AM
, Uzoni
A
, Popa-Wagner
A
, Andrei
A
, Petcu
EB
. The Role of Oxidative Stress in Etiopathogenesis of Chemotherapy Induced Cognitive Impairment (CICI)-“Chemobrain”
. Aging Dis
. 2016
May
;7
(3
):307
–17
.
[PubMed]
2152-525034.
Joshi
G
, Sultana
R
, Tangpong
J
, Cole
MP
, St Clair
DK
, Vore
M
, et al. Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain
. Free Radic Res
. 2005
Nov
;39
(11
):1147
–54
.
[PubMed]
1071-576235.
Joshi
G
, Aluise
CD
, Cole
MP
, Sultana
R
, Pierce
WM
, Vore
M
, et al. Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain
. Neuroscience
. 2010
Mar
;166
(3
):796
–807
.
[PubMed]
0306-452236.
Dubovický
M
. Neurobehavioral manifestations of developmental impairment of the brain
. Interdiscip Toxicol
. 2010
Jun
;3
(2
):59
–67
.
[PubMed]
1337-685337.
Ludeman
SM
. The chemistry of the metabolites of cyclophosphamide
. Curr Pharm Des
. 1999
Aug
;5
(8
):627
–43
.
[PubMed]
1381-612838.
Arumugam
N
, Sivakumar
V
, Thanislass
J
, Devaraj
H
. Effects of acrolein on rat liver antioxidant defense system
. Indian J Exp Biol
. 1997
Dec
;35
(12
):1373
–4
.
[PubMed]
0019-518939.
Elnazer
HY
, Baldwin
DS
. Investigation of cortisol levels in patients with anxiety disorders: a structured review
. Curr Top Behav Neurosci
. 2014
;18
:191
–216
.
[PubMed]
1866-337040.
Kwatra
M
, Jangra
A
, Mishra
M
, Sharma
Y
, Ahmed
S
, Ghosh
P
, et al. Naringin and Sertraline Ameliorate Doxorubicin-Induced Behavioral Deficits Through Modulation of Serotonin Level and Mitochondrial Complexes Protection Pathway in Rat Hippocampus
. Neurochem Res
. 2016
Sep
;41
(9
):2352
–66
.
[PubMed]
0364-319041.
El-Agamy
SE
, Abdel-Aziz
AK
, Esmat
A
, Azab
SS
. Chemotherapy and cognition: comprehensive review on doxorubicin-induced chemobrain
. Cancer Chemother Pharmacol
. 2019
Jul
;84
(1
):1
–14
.
[PubMed]
0344-5704© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
